MENU

Press Releases

  1. Nov 22, 2016

    • AmorChem Sells CF Assets to Vertex Pharmaceuticals

    Read more »

  2. Nov 26, 2014

    Amorchem

    NEWS RELEASE

    Montreal,  November 26,  2014 – Amorchem and Univalor are very pleased to be launching a project with Dr. John Stagg (Institut du cancer de Montréal, Centre de recherché du Centre Hospitalier de l’Université de Montréal) the winner of AmorChem’s first Knock-Out(TM) Event. This project focuses on the development of a new therapeutic strategy to combat cancer.
    Read more »

  3. Jun 29, 2014

    Amorchem

    MEDIA RELEASE

    Basel, Switzerland, and Montreal, Canada – 29 July 2014

    Roche (SIX: RO, ROG; OTCQX: RHHBY) and AmorChem L.P., a Montreal-based venture capital firm investing in life science projects, today announced they have entered into a collaboration to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1, or Steinert’s disease. Myotonic dystrophy is a progressive degenerative disease that affects an estimated 130,000 people in US, EU and Japan. There is currently no approved treatment available to slow or stop disease progression.
    Read more »

  4. Jun 17, 2014

    Amorchem

    NEWS RELEASE

    Montreal,  June  17,  2014 – AmorChem is entering into a collaboration with two well-­known McGill researchers, Dr David Y. Thomas (Professor, Department of Biochemistry) and Dr. John W. Hanrahan (Professor, Department of Physiology), in order to develop novel small molecules which could be used in the treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Dr Thomas and Hanrahan are also co-­founders of Traffick Therapeutics, Inc., a company dedicated to the development of novel molecules able to chaperone defective proteins as they traffic from the endoplasmic reticulum where they are made to the surface of cells where they function, for example, as ion channels.
    Read more »

  5. Oct 28, 2013

    Amorchem     Bellus

    NEWS RELEASE
    LAVAL, Quebec, October 28, 2013 – BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a drug development company focussed on rare diseases, today announced an agreement with AmorChem Holdings Inc. (“AmorChem”) to develop drug candidates for the treatment of AL amyloidosis.

     

    “This partnership for AL amyloidosis enables the Company to continue strengthening its pipeline of rare disease programs that include Kiacta in Phase III for AA amyloidosis, and clinical-stage Shigamabs for STEC-related Hemolytic Uremic Syndrome,” said Roberto Bellini, Chief Executive Officer of BELLUS Health. “The transaction is cash neutral and non-dilutive for BELLUS Health while still providing shareholders a significant stake in the program.”
    Read more »

  6. Sep 19, 2013

    Amorchem     Univalor

    NEWS RELEASE
    Montreal, September 19, 2013 – Following the announcement made on September 17 by the Ministère de l’Enseignement supérieur, de la Recherche, de la Science et de la Technologie du Québec, AmorChem is delighted to announce the closing of a new transaction with Univalor. This undertaking is based on the work of the Dr. Pascal Chartrand (Department of Biochemistry, Université de Montréal) and concerns the development of a therapeutic for treating the symptoms of myotonic dystrophy (Type I).
    Read more »

  7. May 21, 2013

    Amorchem     Univalor

    PRESS RELEASE
    Montreal, May 21, 2013 – AmorChem and Univalor are proud to announce the closing of a reinvestment in the project led by Dr. Nabil Seidah (Institut de recherches cliniques de Montréal). This project, launched in March 2012, is focused on finding drugs which can interact with PCSK9, a well-known target which pharmaceutical companies are pursuing in the treatment of hypercholesterolemia.
    Read more »

  8. Apr 18, 2013

    Amorchem      Univalor

    NEWS RELEASE
    Montreal, Quebec – April 18, 2013 – AmorChem and Univalor are proud to announce a new project focused on discovering drugs directed against a novel target for type 2 diabetes called ABHD6. The project centers on pioneering work accomplished by Dr. Marc Prentki’s team at the Montreal Diabetes Centre and the University of Montreal Hospital Research Centre (CRCHUM). NuChem Therapeutics Inc. (a subsidiary of AmorChem) will carry out the chemistry work.

     

    Diabetes is a disease which affects over 366 million people worldwide. It is a chronic disease with important side effects affecting the kidneys, as well as the cardiovascular and peripheral nervous systems. Globally, eight people die every minute from the consequences of diabetes. Doctors need a large selection of treatment modalities to treat their patients over the long term. The modulation of the target in this project allows for the glucose-sensitive control of insulin secretion, which helps reduce the risk of patients being exposed to unnecessarily high levels of insulin.
    Read more »

  9. Feb 11, 2013

    Amorchem

    NEWS RELEASE
    Montreal, February 11, 2013 – AmorChem is delighted to announce the closing of a transaction to pursue the development of a family of novel DNA methyl transferase inhibitors (DNMTIs). Based on an epigenetics mechanism, these drugs have the potential to be used in the treatment of certain types of cancers, most notably certain hematological cancers.

     

    The work financed by AmorChem will take place in the laboratory of Dr. Richard Momparler, researcher at the Sainte-Justine University Hospital Center and professor, Department of Pharmacology, at the Université de Montréal Dr. Momparler is an expert in the evaluation of experimental chemotherapeutic agents. In addition, some chemistry work will be conducted at NuChem Therapeutics, a Montreal-based medicinal chemistry CRO which is wholly-owned by AmorChem.
    Read more »

  10. Apr 03, 2012

    Amorchem

    PRESS RELEASE
    Montreal, Quebec – April 3, 2012– AmorChem is delighted to announce the closing of a deal with Univalor, the Institut de recherches cliniques de Montréal (“IRCM”) and Dr. Nabil Seidah to pursue the discovery of a new drug to control cholesterol levels. This drug will hit a target called PCSK9, which, when blocked, leads to the significant lowering of cholesterol levels in the blood.

     

    Dr. Nabil Seidah is a pioneer in the field of PCSK9 research and has been working for many years to develop a therapeutic application for the target. “AmorChem is honoured to be collaborating with Dr. Seidah, a world-class scientist and leader in PCSK9 research” explains Dr. Elizabeth Douville from AmorChem. “The importance of PCSK9 was certainly highlighted recently by several companies’ announcements at the Annual Meeting of the American College of Cardiology” she added.
    Read more »